U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma
DE CLARO, R. Angelo, MCGINN, Karen, ROTHMANN, Mark, SHAPIRO, Marjorie, BORREGO, Francisco, CLOUSE, Kathleen, XIAO HONG CHEN, BROWN, Janice, AKINSANYA, Lara, KANE, Robert, KAMINSKAS, Edvardas, FARRELL, Ann, KWITKOWSKI, Virginia, PAZDUR, Richard, BULLOCK, Julie, KHANDELWAL, Aakanksha, HABTEMARIAM, Bahru, OUYANG, Yanli, SABER, Haleh, LEE, Kyung, KOTI, Kallappa
Published in Clinical cancer research (01.11.2012)
Published in Clinical cancer research (01.11.2012)
Get full text
Journal Article